259 related articles for article (PubMed ID: 10377223)
1. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
2. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
4. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
8. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
9. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Schafer PH; Siekierka JJ
J Med Chem; 1998 Oct; 41(22):4196-8. PubMed ID: 9784093
[No Abstract] [Full Text] [Related]
10. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
[TBL] [Abstract][Full Text] [Related]
13. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles.
Pierre Koch ; Christiane Bäuerlein ; Hartmut Jank ; Stefan Laufer
J Med Chem; 2008 Sep; 51(18):5630-40. PubMed ID: 18763757
[TBL] [Abstract][Full Text] [Related]
18. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]